Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P22455
UPID:
FGFR4_HUMAN
Alternative names:
-
Alternative UPACC:
P22455; G3JVM2; G3JVM5; G3JVM7; G3JVM9; O43785; Q14309; Q71TW8; Q8TDA0; Q96KE5
Background:
Fibroblast growth factor receptor 4 (FGFR4) is a tyrosine-protein kinase that serves as a cell-surface receptor for fibroblast growth factors. It is pivotal in regulating cell proliferation, differentiation, migration, lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism, and phosphate homeostasis. FGFR4's activation leads to signaling cascades that involve phosphorylation of PLCG1 and FRS2, crucial for various cellular processes.
Therapeutic significance:
Understanding the role of Fibroblast growth factor receptor 4 could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways underscores its potential as a target for therapeutic intervention in diseases where these pathways are dysregulated.